Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but ...

Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business. 10 stocks we like better than Teva ...

Teva (TEVA) was climbing over 2% on Thursday following seven consecutive sessions of declines. The stock was up 1.71% to $32.10 during midday trading. It ended in the red in each session from July 7 ...

האתר עושה שימוש בעוגיות (Cookies) לצורך שיפור חוויית המשתמש, ניתוח נתוני גלישה והתאמת תכנים אישית. המשך הגלישה באתר מהווה ...

It's no longer a secret that the Teva Pharmaceutical Industries (NYSE: TEVA) of the past is no more. The Israel-based company is no longer strictly a generic-drug maker, burdened by heavy debt and ...

The fund increased its Teva stake, which now accounts for 7.51% of 13F AUM and ranks as its 4th-largest holding. Top holdings after the filing: NYSE:CVS: $617.96 million (13.8% of AUM) NYSE:THC: ...

Teva Pharmaceutical is one of the world's largest generic drug companies. Teva is working to differentiate itself in generics by focusing on harder-to-produce drugs. Teva has begun manufacturing its ...

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Teva Pharmaceutical Industries (NYSE: TEVA) will unveil its first-quarter results this Wednesday, April 29. Many Teva trackers will be watching for validation of the company's continuing strategic ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.